Semaglutide 2.4 mg in Patients With Poor Weight-loss
NCT05073835
Active Not Recruiting
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric by... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/05/2024
Locations: Janine Makaronids, London, Not set
Conditions: Obesity, Diabetes, Metabolic Syndrome
Register for Updates
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
Active Not Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2024
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3, Chandler, Arizona +174 locations
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Register for Updates
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
NCT04862923
Completed
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. Participants will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Master Centre for United Kingdom, Crawley, Not set
Conditions: Diabetes Mellitus, Type 2
Register for Updates
The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes
NCT06318442
Recruiting
TITLE: How GLP-1 Analogues prevent steroid-induced diabetes (The GAPSID Study) DESIGN: A double-blind study evaluating how GLP-1 analogues, compared with metformin, prevent hyperglycaemia in response to a 7-day course of dexamethasone (DEX) 6 mg once daily. This is a mechanistic experimental medicine study. AIMS: To evaluate the mechanisms by which GLP-1 analogues reduce steroid-induced hyperglycaemia compared to metformin. OUTCOME MEASURES: * Primary: Glucose tolerance in response to standa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Imperial College Healthcare NHS Trust, London, Not set
Conditions: Steroid-Induced Diabetes, Steroid Induced Hyperglycemia
Register for Updates
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Register for Updates
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
NCT03987451
Completed
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is decided by chance. The study will last for about 61 weeks in total. Participants will have 10 clinic visits and 3 phone calls with the study doctor or staff during the study. Some of the clinic visits may be spread over more days. Participants will need to inject themse... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: Arizona Liver Health, Chandler, Arizona +37 locations
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
NCT05646199
Not Yet Recruiting
The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period. The main question it aims to answer is: • Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS? Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally.... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/08/2024
Locations: Hull University Teaching Hospitals NHS Trust, Hull, Not set
Conditions: Polycystic Ovary Syndrome
Register for Updates
A Study of Cardiovascular Events iN Diabetes Plus
NCT05441267
Recruiting
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/07/2024
Locations: Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, Not set
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
NCT05232708
Completed
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 su... Read More
Gender:
ALL
Ages:
Between 20 years and 55 years
Trial Updated:
01/25/2024
Locations: Parexel CPRU, Level 7, Harrow, Middlesex
Conditions: Healthy Volunteers (Diabetes Mellitus, Type 2)
Register for Updates
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
NCT04102189
Completed
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - wh... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/29/2023
Locations: Novo Nordisk Investigational Site, Meridian, Idaho +36 locations
Conditions: Overweight, Obesity
Register for Updates
Semaglutide Use in Acute Pulmonary Embolism
NCT06118203
Completed
Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/03/2023
Locations: Colm McCabe, London, Not set
Conditions: Pulmonary Embolism
Register for Updates
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
NCT04513704
Completed
The goal of this trial is to find out whether taking semaglutide tablets at different times before and after eating has a similar effect compared to the recommended dosing time. Participants with type 2 diabetes are recommended to take semaglutide on an empty stomach, and they should not eat, drink, or take any oral medicine for at least 30 minutes after that. The trial will look at how different dosing times of semaglutide before and after eating a meal changes how much semaglutide participants... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/11/2023
Locations: Novo Nordisk Investigational Site, Harrow, Not set
Conditions: Healthy Volunteers Type 2 Diabetes
Register for Updates